Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells

Molecular and Cellular Biochemistry

Volumn 410, Issue 1-2, 2015, Pages 293-300

  Bohanon, Fredrick J ^a,b   Wang, Xiaofu ^a   Graham, Brittany M ^a   Prasai, Anesh ^a,b   Vasudevan, Sadhashiva J ^a   Ding, Chunyong ^a   Ding, Ye ^a   Radhakrishnan, Geetha L ^a   Rastellini, Cristiana ^a   Zhou, Jia ^a   Radhakrishnan, Ravi S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

Apoptosis; ECM; Liver fibrosis; Oridonin; Stellate cells

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; CASPASE 3; CASPASE 9; CELL PROTEIN; COLLAGEN TYPE 1; CYCLIN B1; CYD 0692; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORIDONIN; PROTEIN P21; PROTEIN P53; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN; CYD0682; KAURANE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL VIABILITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; LIVER FIBROSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RESAZURIN ASSAY; S PHASE CELL CYCLE CHECKPOINT; STELLATE CELL; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL PROLIFERATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; RAT; TIME FACTOR;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; CELL LINE; CELL PROLIFERATION; DITERPENES, KAURANE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER CIRRHOSIS; RATS; S PHASE CELL CYCLE CHECKPOINTS; TIME FACTORS;

EID: 84946482175     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2562-4     Document Type: Article

References (33)

1. Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A, Parola M (2014) Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys 548:20–37. doi:10.1016/j.abb.2014.02.015
2. Zhang Y, Ghazwani M, Li J, Sun M, Stolz DB, He F, Fan J, Xie W, Li S (2014) MiR-29b inhibits collagen maturation in hepatic stellate cells through down-regulating the expression of HSP47 and lysyl oxidase. Biochem Biophys Res Commun 446:940–944. doi:10.1016/j.bbrc.2014.03.037
3. Benyon RC, Arthur MJ (2001) Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 21:373–384. doi:10.1055/s-2001-17552
4. Asahina K (2012) Hepatic stellate cell progenitor cells. J Gastroenterol Hepatol 27(Suppl 2):80–84. doi:10.1111/j.1440-1746.2011.07001.x
5. Lemoinne S, Cadoret A, El Mourabit H, Thabut D, Housset C (2013) Origins and functions of liver myofibroblasts. Biochim Biophys Acta 1832:948–954. doi:10.1016/j.bbadis.2013.02.019
6. Tsukamoto H, Zhu NL, Wang J, Asahina K, Machida K (2012) Morphogens and hepatic stellate cell fate regulation in chronic liver disease. J Gastroenterol Hepatol 27(Suppl 2):94–98. doi:10.1111/j.1440-1746.2011.07022.x
7. Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, Lam RW, Zhang GC, Zhang H, Ye T (2011) Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 55:612–625. doi:10.1016/j.jhep.2010.11.035
8. Lee SH, Seo GS, Park YN, Yoo TM, Sohn DH (2004) Effects and regulation of osteopontin in rat hepatic stellate cells. Biochem Pharmacol 68:2367–2378. doi:10.1016/j.bcp.2004.08.022
9. Ramm GA, Shepherd RW, Hoskins AC, Greco SA, Ney AD, Pereira TN, Bridle KR, Doecke JD, Meikle PJ, Turlin B, Lewindon PJ (2009) Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 49:533–544. doi:10.1002/hep.22637
10. Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, Modlin RL, Liblau RS, Gressner AM, Kaufmann SH (2007) Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 26:117–129. doi:10.1016/j.immuni.2006.11.011
11. Schuppan D, Kim YO (2013) Evolving therapies for liver fibrosis. J Clin Invest 123:1887–1901. doi:10.1172/JCI66028
12. Bohanon FJ, Wang X, Ding C, Ding Y, Radhakrishnan GL, Rastellini C, Zhou J, Radhakrishnan RS (2014) Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis. J Surg Res 190:55–63. doi:10.1016/j.jss.2014.03.036
13. Ding C, Zhang Y, Chen H, Yang Z, Wild C, Ye N, Ester CD, Xiong A, White MA, Shen Q, Zhou J (2013) Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J Med Chem 56:8814–8825. doi:10.1021/jm401248x
14. Ding C, Zhang Y, Chen H, Wild C, Wang T, White MA, Shen Q, Zhou J (2013) Overcoming synthetic challenges of oridonin A-ring structural diversification: regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position. Org Lett 15:3718–3721. doi:10.1021/ol4015865
15. Ding C, Zhang Y, Chen H, Yang Z, Wild C, Chu L, Liu H, Shen Q, Zhou J (2013) Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J Med Chem 56:5048–5058. doi:10.1021/jm400367n
16. Ding C, Wang L, Chen H, Wild C, Ye N, Ding Y, Wang T, White MA, Shen Q, Zhou J (2014) ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids. Org Biomol Chem 12:8442–8452. doi:10.1039/c4ob01040j
17. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
18. Kelly JH, Darlington GJ (1989) Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2. In Vitro Cell Dev Biol 25:217–222
19. David B, Dufresne M, Nagel MD, Legallais C (2004) In vitro assessment of encapsulated C3A hepatocytes functions in a fluidized bed bioreactor. Biotechnol Prog 20:1204–1212. doi:10.1021/bp034301z
20. Sarkar FH, Li Y (2006) Markers of apoptosis. Methods Mol Med 120:147–160
21. Fujisawa S, Romin Y, Barlas A, Petrovic LM, Turkekul M, Fan N, Xu K, Garcia AR, Monette S, Klimstra DS, Erinjeri JP, Solomon SB, Manova-Todorova K, Sofocleous CT (2014) Evaluation of YO-PRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases. Cytotechnology 66:259–273. doi:10.1007/s10616-013-9565-3
22. Yoshida K, Matsuzaki K (2012) Differential regulation of TGF-β/Smad Signaling in hepatic stellate cells between acute and chronic liver injuries. Front Physiol 3:53. doi:10.3389/fphys.2012.00053
23. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20:1803–1815. doi:10.1038/sj.onc.1204252
24. Charrier-Savournin FB, Château MT, Gire V, Sedivy J, Piette J, Dulic V (2004) p21-Mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress. Mol Biol Cell 15:3965–3976. doi:10.1091/mbc.E03-12-0871
25. Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, Ikejima T (2007) P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin 28:1057–1066. doi:10.1111/j.1745-7254.2007.00588.x
26. Matsuzaki K (2009) Modulation of TGF-beta signaling during progression of chronic liver diseases. Front Biosci (Landmark Ed) 14:2923–2934
27. Mulder KM (2000) Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 11:23–35
28. Xu W, Sun J, Zhang TT, Ma B, Cui SM, Chen DW, He ZG (2006) Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol Sin 27:1642–1646. doi:10.1111/j.1745-7254.2006.00440.x
29. Chen G, Wang K, Yang BY, Tang B, Chen JX, Hua ZC (2012) Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol 40:139–147. doi:10.3892/ijo.2011.1210
30. Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T (2004) Oridonin induces a caspase-independent but mitochondria- and MAPK-dependent cell death in the murine fibrosarcoma cell line L929. Biol Pharm Bull 27:1527–1531
31. Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z (2007) Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 109:3441–3450. doi:10.1182/blood-2006-06-032250
32. Li S, Liu Y, Liu T, Zhao L, Zhao J, Feng N (2011) Development and in vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique. Int J Pharm 411:172–177. doi:10.1016/j.ijpharm.2011.04.006
33. Tian W, Chen SY (2013) Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin. Chin J Integr Med 19:315–320. doi:10.1007/s11655-013-1437-3